U.S. Machinery Stock News

NasdaqCM:CLPT
NasdaqCM:CLPTMedical Equipment

Can ClearPoint Neuro’s (CLPT) New Robotic Platform Redefine Its Clinical Expansion Trajectory?

ClearPoint Neuro recently announced the appointment of Dr. Paul Larson as Chief Medical Officer, the unveiling of its proprietary Robotic Neuro-Navigation System for minimally invasive cranial procedures, and new insider buying from directors. The Robotic Neuro-Navigation System aims to provide greater consistency for cell and gene therapy delivery, and ClearPoint's drug delivery technology was spotlighted in strong Huntington's disease trial results from a biopharma collaborator. Let's...
NasdaqCM:RITR
NasdaqCM:RITRReal Estate

Will Reitar Logtech Holdings' (RITR) AI Logistics Push in Qatar Reshape Its Global Expansion Narrative?

Reitar Logtech Holdings recently announced the formal signing of a Strategic Cooperation Memorandum of Understanding with AI logistics company NEXX to jointly invest in a Smart Fulfillment Center project in Doha, Qatar, as part of broad plans for logistics automation in the region. This initiative not only launches a large-scale, AI-driven logistics facility but also aligns with Qatar's 2030 National Vision and the digital corridor ambitions of China's Belt and Road Initiative. We'll explore...
NasdaqGS:TDUP
NasdaqGS:TDUPSpecialty Retail

Examining ThredUp Stock After Its 1100% Rally Amid Surging Resale Market Momentum

If you have been watching ThredUp lately, you know it is one of those rare stocks that keeps drawing your attention. Whether you are holding after that massive 1-year surge or you are still weighing your next move, there is a lot to unpack. ThredUp has soared an eye-catching 1111.0% over the last year, with a staggering 568.8% gain year-to-date. Even after a recent 30-day dip of -10.7%, it has still notched a respectable 2.4% gain in the past week. This reminds investors that volatility can...
NasdaqCM:OVID
NasdaqCM:OVIDBiotechs

Ovid Therapeutics (OVID) Is Up 6.4% After Positive Phase 1 Results for Drug-Resistant Epilepsy Candidate

Ovid Therapeutics recently announced positive topline results from its Phase 1 study of OV329, a next-generation GABA-aminotransferase inhibitor targeting drug-resistant epilepsies, demonstrating significant GABAergic inhibition and strong safety outcomes in 68 healthy volunteers. This clinical milestone signals potential advancement in the treatment of drug-resistant epilepsies and attracted new institutional investors through a substantial private placement. We'll explore how OV329’s early...
NasdaqCM:ZURA
NasdaqCM:ZURABiotechs

Does Zura Bio's (ZURA) Severance Plan Reflect Management's Priorities Amid Cash Burn Pressures?

On September 24, 2025, Zura Bio Limited adopted an Executive Severance Benefit Plan, outlining compensation for executives if terminated without cause or upon resignation for good reason, especially in the context of a change in control. This move comes as the company, which reported having US$154 million in cash with a reported runway of 3.5 years as of June 2025, faces scrutiny over its increasing cash burn and potential funding needs. We'll examine how concerns around Zura Bio's executive...
NYSE:ALEX
NYSE:ALEXREITs

Is There Now an Opportunity in Alexander & Baldwin After Recent Q1 Earnings Results?

If you’ve been scanning the markets wondering whether now is the right time to buy, hold, or move on from Alexander & Baldwin, you’re not alone. This stock can puzzle even seasoned investors, especially after a rollercoaster of performance. Over the past five years, Alexander & Baldwin’s price has soared nearly 80%, which is impressive for a real estate-focused name. Those who’ve sat tight since 2021 are still up over 22% despite the flat year-over-year returns, and a slight dip of -0.4% in...
NYSE:ZWS
NYSE:ZWSBuilding

Does Zurn Elkay Still Offer Value After Climbing Nearly 30% in the Past Year?

Thinking about what to do with Zurn Elkay Water Solutions stock? You are not alone. Investors have watched this water solutions company steadily climb, with shares up 4.9% in the last 30 days and a whopping 29.9% over the past year. The longer-term numbers are even more eye-catching, showing a return of 96.6% over three years and a stunning 217.9% run across five years. After a quieter week, with the stock up just 0.1%, some might wonder if the stock is catching its breath for another sprint...
NYSE:SCS
NYSE:SCSCommercial Services

Does Steelcase’s 47.6% Rally in 2025 Signal Room for More Gains?

If you’ve been watching Steelcase stock lately, you’re not alone. Whether you’re wondering if now is the time to buy, hold, or cash in some gains, there’s plenty to consider. After notching a 0.7% gain in just the last week, and more than doubling investors’ money over the past three years with a 171.5% return, Steelcase has certainly caught the market’s attention. That momentum is not just a blip; with a 47.6% gain year-to-date, the company’s upward move reflects both a renewed sense of...